Fda

Use of aromatase inhibitor forms basis of warning letter

Use of aromatase inhibitor forms basis of warning letter

By Hank Schultz

A recently posted warning letter cites a New York company for the presence of an aromatase inhibitor in one of its dietary supplements. This class of chemicals is popular with strength trainers for its purported ability to suppress estrogen levels.

Letter to FDA seeks clarity on agency’s resources, enforcement aims

Archive article of the week

Letter to FDA seeks clarity on agency’s resources, enforcement aims

By Hank Schultz

Three members of Congress have sent a letter to the US Food and Drug Administration requesting specifics on how enforcement funds are allocated. The three lawmakers are among those the Council for Responsible Nutrition has worked closely with on regulatory...

© Getty Images / Aryut

Archive article of the week

‘Needed’: FDA issues draft guidance for best practices for GRAS panels

By Stephen Daniells

Hailed by experts as ‘needed’ and ‘significant’, the US Food and Drug Administration has issued draft guidance on best practices to follow when convening a panel of experts to evaluate whether a substance is “generally recognized as safe” (GRAS).

© Getty Images / NithidPhoto

Supplement trade associations and USADA warn consumers about SARMs

By Stephen Daniells

The dietary supplement industry’s leading trade associations and the US Anti-Doping Agency have voiced their support of the recent FDA actions to protect consumers from body-building products containing Selective Androgen Receptor Modulators (SARMs) illegally...

FDA hardens stance against use of CBD in supplements

FDA hardens stance against use of CBD in supplements

By Hank Schultz

The Food and Drug Administration’s attitude that CBD does not belong in dietary supplements seems to have hardened, judging by the wording of four warning letters issued this week.

Spotlight

Follow us

Featured Events

View more

Products

View more

Webinars

Featured Suppliers

All suppliers